Cargando…

Dysregulation of CXCL9 and reduced tumor growth in Egr-1 deficient mice

BACKGROUND: Early growth response-1 (Egr-1) is an immediate-early transcription factor inducible in the vasculature in response to injury, shear stress, and other stimuli. Mice lacking Egr-1 have a profound deficit in the ability to recover from femoral artery ligation, suggesting a role in neovascu...

Descripción completa

Detalles Bibliográficos
Autores principales: Caso, Giuseppe, Barry, Catherine, Patejunas, Gerald
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654460/
https://www.ncbi.nlm.nih.gov/pubmed/19200397
http://dx.doi.org/10.1186/1756-8722-2-7
_version_ 1782165366738255872
author Caso, Giuseppe
Barry, Catherine
Patejunas, Gerald
author_facet Caso, Giuseppe
Barry, Catherine
Patejunas, Gerald
author_sort Caso, Giuseppe
collection PubMed
description BACKGROUND: Early growth response-1 (Egr-1) is an immediate-early transcription factor inducible in the vasculature in response to injury, shear stress, and other stimuli. Mice lacking Egr-1 have a profound deficit in the ability to recover from femoral artery ligation, suggesting a role in neovascularization. Previous studies have shown that manipulating Egr-1 expression can have either positive or negative effects on tumor growth. We hypothesized that Egr-1 knockout mice might exhibit reduced tumor growth, possibly due to a reduced capacity to respond to angiogenic signals from a growing tumor. RESULTS: We injected 10(6 )Lewis lung carcinoma (LLC1) cells subcutaneously in the flank of wild type and Egr-1 knockout mice. The average mass of tumors from wild type mice at 12 days after implantation was 413 +/- 128 mg, while those from Egr-1(-/- )mice was 219 +/- 81 mg (p = 0.001, mean +/- SD). However, sectioning the tumors and staining with anti-CD31 antibodies revealed no difference in the vascularity of the tumors and there was no difference in angiogenic growth factor expression. Expression of the chemokine Mig (CXCL9) was increased 2.8-fold in tumors from knockout mice, but no increase was found in serum levels of Mig. Natural killer cells have a 1.7-fold greater prevalence in the CD45(+ )cells found in tumors from Egr-1(-/- )mice compared to those from wild type mice. Immunohistochemical staining suggests that Mig expression in the tumors comes from invading macrophages. CONCLUSION: Mice deficient in Egr-1 exhibit reduced growth of LLC1 tumors, and this phenomenon is associated with overexpression of Mig locally within the tumor. There are no obvious differences in tumor vascularity in the knockout mice. Natural killer cells accumulate in the tumors grown in Egr-1(-/- )mice, providing a potential mechanism for the reduction in growth.
format Text
id pubmed-2654460
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26544602009-03-12 Dysregulation of CXCL9 and reduced tumor growth in Egr-1 deficient mice Caso, Giuseppe Barry, Catherine Patejunas, Gerald J Hematol Oncol Research BACKGROUND: Early growth response-1 (Egr-1) is an immediate-early transcription factor inducible in the vasculature in response to injury, shear stress, and other stimuli. Mice lacking Egr-1 have a profound deficit in the ability to recover from femoral artery ligation, suggesting a role in neovascularization. Previous studies have shown that manipulating Egr-1 expression can have either positive or negative effects on tumor growth. We hypothesized that Egr-1 knockout mice might exhibit reduced tumor growth, possibly due to a reduced capacity to respond to angiogenic signals from a growing tumor. RESULTS: We injected 10(6 )Lewis lung carcinoma (LLC1) cells subcutaneously in the flank of wild type and Egr-1 knockout mice. The average mass of tumors from wild type mice at 12 days after implantation was 413 +/- 128 mg, while those from Egr-1(-/- )mice was 219 +/- 81 mg (p = 0.001, mean +/- SD). However, sectioning the tumors and staining with anti-CD31 antibodies revealed no difference in the vascularity of the tumors and there was no difference in angiogenic growth factor expression. Expression of the chemokine Mig (CXCL9) was increased 2.8-fold in tumors from knockout mice, but no increase was found in serum levels of Mig. Natural killer cells have a 1.7-fold greater prevalence in the CD45(+ )cells found in tumors from Egr-1(-/- )mice compared to those from wild type mice. Immunohistochemical staining suggests that Mig expression in the tumors comes from invading macrophages. CONCLUSION: Mice deficient in Egr-1 exhibit reduced growth of LLC1 tumors, and this phenomenon is associated with overexpression of Mig locally within the tumor. There are no obvious differences in tumor vascularity in the knockout mice. Natural killer cells accumulate in the tumors grown in Egr-1(-/- )mice, providing a potential mechanism for the reduction in growth. BioMed Central 2009-02-07 /pmc/articles/PMC2654460/ /pubmed/19200397 http://dx.doi.org/10.1186/1756-8722-2-7 Text en Copyright © 2009 Caso et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Caso, Giuseppe
Barry, Catherine
Patejunas, Gerald
Dysregulation of CXCL9 and reduced tumor growth in Egr-1 deficient mice
title Dysregulation of CXCL9 and reduced tumor growth in Egr-1 deficient mice
title_full Dysregulation of CXCL9 and reduced tumor growth in Egr-1 deficient mice
title_fullStr Dysregulation of CXCL9 and reduced tumor growth in Egr-1 deficient mice
title_full_unstemmed Dysregulation of CXCL9 and reduced tumor growth in Egr-1 deficient mice
title_short Dysregulation of CXCL9 and reduced tumor growth in Egr-1 deficient mice
title_sort dysregulation of cxcl9 and reduced tumor growth in egr-1 deficient mice
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654460/
https://www.ncbi.nlm.nih.gov/pubmed/19200397
http://dx.doi.org/10.1186/1756-8722-2-7
work_keys_str_mv AT casogiuseppe dysregulationofcxcl9andreducedtumorgrowthinegr1deficientmice
AT barrycatherine dysregulationofcxcl9andreducedtumorgrowthinegr1deficientmice
AT patejunasgerald dysregulationofcxcl9andreducedtumorgrowthinegr1deficientmice